
BioSyent Inc. – TSX:RX.V
BioSyent stock price today
BioSyent stock price monthly change
BioSyent stock price quarterly change
BioSyent stock price yearly change
BioSyent key metrics
Market Cap | 103.43M |
Enterprise value | 122.96M |
P/E | 18.91 |
EV/Sales | 3.56 |
EV/EBITDA | 12.39 |
Price/Sales | 3.90 |
Price/Book | 3.59 |
PEG ratio | 0.96 |
EPS | 0.59 |
Revenue | 32.84M |
EBITDA | 9.20M |
Income | 7.05M |
Revenue Q/Q | 19.29% |
Revenue Y/Y | 19.98% |
Profit margin | 20.6% |
Oper. margin | 23.93% |
Gross margin | 78.73% |
EBIT margin | 23.93% |
EBITDA margin | 28.04% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioSyent stock price history
BioSyent stock forecast
BioSyent financial statements
Jun 2023 | 7.96M | 1.48M | 18.63% |
---|---|---|---|
Sep 2023 | 8.87M | 2.35M | 26.5% |
Dec 2023 | 8.27M | 1.45M | 17.54% |
Mar 2024 | 7.73M | 1.76M | 22.87% |
2025 | 38.7M | 6.81M | 17.61% |
---|---|---|---|
2026 | 42.5M | 7.78M | 18.33% |
Analysts Price target
Financials & Ratios estimates
Payout ratio | 28.69% |
---|
2019 | |
---|---|
2020 | |
2021 | |
2022 | 0.56% |
2023 | 1.79% |
Jun 2023 | 39512935 | 6.44M | 16.31% |
---|---|---|---|
Sep 2023 | 41396711 | 6.84M | 16.54% |
Dec 2023 | 41528939 | 6.76M | 16.3% |
Mar 2024 | 39996434 | 5.44M | 13.61% |
Jun 2023 | 3.07M | 1.82M | -2.03M |
---|---|---|---|
Sep 2023 | 2.40M | -976.08K | -1.13M |
Dec 2023 | 822.70K | -1.06M | -1.28M |
Mar 2024 | 1.27M | -39.20K | -2.16M |
BioSyent other data
-
What's the price of BioSyent stock today?
One share of BioSyent stock can currently be purchased for approximately $7.2.
-
When is BioSyent's next earnings date?
Unfortunately, BioSyent's (RX.V) next earnings date is currently unknown.
-
Does BioSyent pay dividends?
Yes, BioSyent pays dividends and its trailing 12-month yield is 1.55% with 29% payout ratio. The last BioSyent stock dividend of undefined was paid on 4 Sep 2025.
-
How much money does BioSyent make?
BioSyent has a market capitalization of 103.43M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.12% to 31.59M US dollars.
-
What is BioSyent's stock symbol?
BioSyent Inc. is traded on the TSX under the ticker symbol "RX.V".
-
What is BioSyent's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.
-
How do i buy shares of BioSyent?
Shares of BioSyent can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
When BioSyent went public?
BioSyent Inc. is publicly traded company for more then 29 years since IPO on 8 May 1996.
-
What is BioSyent's official website?
The official website for BioSyent is biosyent.com.
-
Where are BioSyent's headquarters?
BioSyent is headquartered at 2476 Argentia Road, Mississauga, ON.
-
How can i contact BioSyent?
BioSyent's mailing address is 2476 Argentia Road, Mississauga, ON.
BioSyent company profile:

BioSyent Inc.
biosyent.comTSX
0
Drug Manufacturers—Specialty & Generic
Healthcare
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
Mississauga, ON L5N 6M1
:
ISIN: CA0906901081
: